Trastuzumab, a recombinant, humanised IG1 monoclonal antibody, binds selectively to the human epidermal growth factor receptor 2 (EGFR2) and blocks the receptor hindering the uncontrolled proliferation of HER-2-positive cancer cells. Here, ERBB2 is linked to cancer.